Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Barrett

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|October 16, 2014
Chimeric antigen receptor T cells for sustained remissions in leukemiaShannon L Maude, Noelle Frey, Pamela A Shaw, et al.
Journal for Immunotherapy of Cancer|September 27, 2022
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumorsJessica B Foster, Crystal Griffin, Jo Lynne Rokita, et al.
Blood|September 8, 2012
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaShannon L Maude, Sarah K Tasian, Tiffaney Vincent, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical TrialStephan Kadauke, Regina M Myers, Yimei Li, et al.
Blood|December 5, 2021
Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemiaChangya Chen, Wenbao Yu, Fatemeh Alikarami, et al.
Blood|January 7, 2018
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemiaKaren L Bride, Tiffaney L Vincent, Soo-Yeon Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19Caroline Diorio, Rawan Shraim, Regina Myers, et al.
Cancer Discovery|April 15, 2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaDavid T Teachey, Simon F Lacey, Pamela A Shaw, et al.
Nature Communications|April 23, 2025
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesPablo Domizi, Jolanda Sarno, Astraea Jager, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|October 16, 2014
Chimeric antigen receptor T cells for sustained remissions in leukemiaShannon L Maude, Noelle Frey, Pamela A Shaw, et al.
Journal for Immunotherapy of Cancer|September 27, 2022
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumorsJessica B Foster, Crystal Griffin, Jo Lynne Rokita, et al.
Blood|September 8, 2012
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaShannon L Maude, Sarah K Tasian, Tiffaney Vincent, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical TrialStephan Kadauke, Regina M Myers, Yimei Li, et al.
Blood|December 5, 2021
Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemiaChangya Chen, Wenbao Yu, Fatemeh Alikarami, et al.
Blood|January 7, 2018
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemiaKaren L Bride, Tiffaney L Vincent, Soo-Yeon Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19Caroline Diorio, Rawan Shraim, Regina Myers, et al.
Cancer Discovery|April 15, 2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaDavid T Teachey, Simon F Lacey, Pamela A Shaw, et al.
Nature Communications|April 23, 2025
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesPablo Domizi, Jolanda Sarno, Astraea Jager, et al.
Pageof 8